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Background: Investigating tumour evolution and acquired chemotherapy resistance requires analysis of sequential tumour
material. We describe the feasibility of obtaining research biopsies in women with relapsed ovarian high-grade serous carcinoma
(HGSC).
Methods: Women with relapsed ovarian HGSC underwent either image-guided biopsy or intra-operative biopsy during
secondary debulking, and samples were fixed in methanol-based fixative. Tagged-amplicon sequencing was performed on biopsy
DNA.
Results:We screened 519 patients in order to enrol 220. Two hundred and two patients underwent successful biopsy, 118 of which
were image-guided. There were 22 study-related adverse events (AE) in the image-guided biopsies, all grades 1 and 2; pain was
the commonest AE. There were pre-specified significant AE in 3/118 biopsies (2.5%). 87% biopsies were fit-for-purpose for
genomic analyses. Median DNA yield was 2.87 mg, and was higher in biopsies utilising 14 G or 16 G needles compared to 18 G.
TP53 mutations were identified in 94.4% patients.
Conclusions: Obtaining tumour biopsies for research in relapsed HGSC is safe and feasible. Adverse events are rare. The large
majority of biopsies yield sufficient DNA for genomic analyses—we recommend use of larger gauge needles and methanol
fixation for such biopsies, as DNA yields are higher but with no increase in AEs.
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The commonest subtype of ovarian cancer, high-grade serous
carcinoma (HGSC), accounts for B70% all cases, and 80% of
deaths. Genomically, it is defined by near-universal TP53 mutation
(Ahmed et al, 2010; Ko¨bel et al, 2016), widespread copy number
alterations (Gorringe et al, 2010; TCGA, 2011) and loss of
gene function through complex structural rearrangements (Patch
et al, 2015).
HGSC is initially sensitive to platinum-based chemotherapy but
relapse occurs very frequently, with progressive development of
platinum resistance, resulting in poor long-term survival (Mackay
et al, 2010; Oza et al, 2015). Spatial and temporal heterogeneity
have been frequently observed in HGSC, and low-frequency
subclonal populations, which are present at the time of diagnosis,
can undergo expansion during chemotherapy to become the
predominant resistant population (Forshew et al, 2012; Schwarz
et al, 2015). In addition, secondary or revertant mutations in
BRCA1 and BRCA2 may provide alternative mechanisms of
abrogating platinum sensitivity (Edwards et al, 2008; Sakai et al,
2008; Patch et al, 2015).
Establishing accurate estimates of the prevalence of temporal
heterogeneity and divergent evolution in HGSC will require
sequential collection of tumour material at multiple time points
during throughout course of the patient’s disease, especially at
relapse and progression. We and others have already demonstrated
that image-guided biopsies can be obtained in patients with
ovarian cancer (Spencer et al, 2006; Griffin et al, 2009; Swisher
et al, 2017), whilst many early phase clinical trials now include
translational research biopsies to investigate pharmacodynamic
biomarkers. However, there is widespread variation in the
reporting of outcomes of biopsy-driven studies (Freeman et al,
2013) and few data on the utility of these biopsies for complex
genomic studies.
We have established BriTROC, a UK-based ovarian cancer
consortium, which is investigating the acquisition of resistance in
women with HGSC by focussing on the collection of sequential
tumour biopsies, ctDNA and ascites from women with relapsed
HGSC. We present here the interim data from the BriTROC-1
study in order to demonstrate the safety and feasibility of acquiring
tumour biopsies in relapsed ovarian cancer across multiple
academic centres. The secondary aim is to report the utility of
methanol-fixed biopsies for next-generation sequencing analyses
(Piskorz et al, 2016).
PATIENTS AND METHODS
Study conduct. The BriTROC-1 study was funded by Ovarian
Cancer Action and sponsored by NHS Greater Glasgow and Clyde.
A Trial Management Group (TMG, see Supplementary Material 1)
designed and ran the study. Ethics/IRB approval was given by
Cambridge Central Research Ethics Committee (Reference 12/EE/
0349). The primary objective was to demonstrate the safety
and feasibility of acquiring tumour biopsies from women with
relapsed ovarian cancer in multiple centres. The secondary
endpoints were to examine genomic alterations in relapsed ovarian
HGSC. All patients provided written informed consent—this
consent included specific consent to biopsy, use of biopsy material
(and ascites if present) for genomic studies and testing of germline
DNA for BRCA1/2 mutations. In addition, patients could
optionally consent to a second biopsy upon disease progression
and to be informed of germline BRCA1/2 analysis results.
A copy of the patient consent form is included in Supplementary
Material 7.
Significant complications were continuously monitored during
the study. These were defined as gradeX2 events related to image-
guided biopsy, specifically pain, haemorrhage, wound infection and
peritoneal infection. The monitoring process used a one-sided
(upward) CUSUM chart (Lerch et al, 2007) both study-wide and
for individual sites. CUSUM control limits were set using an
acceptable significant complication rate of o5%, an unacceptable
rate of410%, a power of 88% and a significance level of 10%. If an
individual site breached CUSUM control limits, that site was
suspended pending detailed TMG review. If the whole study
breached CUSUM control limits, recruitment was suspended to
allow thorough review.
Patients. The study enrolled patients with recurrent ovarian high-
grade serous or grade 3 endometrioid carcinoma who had relapsed
following at least one line of platinum-based chemotherapy. Other
histological subtypes were only allowed in patients with known
deleterious germline BRCA1 or BRCA2 mutations. All patients had
to have disease amenable either to image-guided or other
interventional (e.g., endoscopy, bronchoscopy) biopsy, or second-
ary debulking surgery. Samples obtained at secondary debulking or
other interventions were jointly classified as ‘surgical’ biopsies.
Access to archival diagnostic formalin-fixed was also required, as
well as snap frozen tumour material if available. Overall survival
was calculated from the date of enrolment to the date of death or
the last clinical assessment, with data cutoff at 1 December 2016.
Full inclusion and exclusion criteria are listed in Supplementary
Material 2.
Patients underwent biopsy (at least two cores, 14–16 G biopsy
needle) or secondary debulking surgery, with tumour samples fixed
in methanol (TissueTek Xpress, Sakura Finetek, Torrance, CA,
USA) (Piskorz et al, 2016). If 14–16 G cores were felt not to be
appropriate (e.g., due to site of disease), three 18 G cores were
taken instead. For patients undergoing secondary debulking or
other interventional biopsies, 14–16 G cores or a 1 cm3 piece of
macroscopically identified tumour tissue were taken. Retrospective
registration was allowed only following consultation with the Chief
Investigator. All samples were shipped within 24 h at ambient
temperature to the University of Glasgow for processing.
All treatment following study entry was at the discretion of the
treating oncologist. Patients optionally also consented to a further
biopsy at subsequent progression.
Sample processing, DNA extraction and quantification.
A detailed laboratory manual was provided to all study sites. After
fixation, tumour samples were processed in a ThermoExcelsior
Tissue Processor using optimised protocols (Piskorz et al, 2016).
Tumour cellularity was determined on H&E staining by a
pathologist with expertise in gynaecological pathology as the
percentage of tumour cells in areas selected for dissection. Up to
forty 10 mm tissue sections per block were macro- or micro-
dissected. DNA was extracted using QIAmp DNA Micro Kit
(Qiagen, Manchester, UK). Quantification was performed by Qubit
2.0 fluorimeter (Life Technologies, Paisley, UK) using dsDNA BR
Assay.
Tagged-amplicon sequencing. The coding regions of TP53, PTEN
and hotspot regions in EGFR, PIK3CA, KRAS and BRAF were
sequenced by tagged-amplicon sequencing (Forshew et al, 2012) on
the MiSeq Sequencing System (Illumina, Cambridge, UK) using
paired-end 125 bp protocols. Sequencing data analysis was
performed as previously (Piskorz et al, 2016).
Statistical analyses. All statistical analyses were performed in
Prism for Mac v.6 (GraphPad, La Jolla, CA, USA) and R (v.3.3.2).
Adverse event (AE) rates were compared using Pearson’s w2-test,
while DNA yields were compared using Wilcoxon rank sum test.
All tests were two-sided and Po0.05 was considered significant.
A complete R markdown document detailing all analyses is
provided as Supplementary Material 8.
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RESULTS
Patients and recruitment. Recruitment started on 4 January 2013
and involved 14 UK centres. Figure 1 summarises the recruitment
and sample numbers. A total of 519 patients were screened
(Figure 1A). One hundred and eighty-two patients were ineligible
and 117 declined to participate. The most frequent cause of
ineligibility was disease deemed not suitable for image-guided
biopsy by expert radiologists. Supplementary Material 3 lists all
reasons for ineligibility and for declining participation.
Table 1 summarises the clinical characteristics of the 220
enrolled patients, of whom 198 (90%) were registered prospectively
and 22 (10%) retrospectively. The median number of prior
chemotherapy lines was 1 (range 1–5) for platinum-sensitive
patients and 2 (range 1–12) for platinum-resistant (Supplementary
Material 4), and 17 patients (7.7%) had received prior bevacizu-
mab. Median overall survival from study entry was 13.4 months for
BA
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Figure 1. Trial profile. (A) Flow of patients and samples in the BriTROC-1 study. *Patients undergoing other interventional biopsies are classified as
‘surgical’. (B) Sample flow from the first 157 patients (B). **Two samples witho200ng DNA were still sufficient for tagged amplicon sequencing analysis.
Table 1. Demographic and disease characteristics
Characteristic
Platinum-sensitive
(N¼171)
Platinum-resistant
(N¼49)
Total
(N¼220)
Median age (range), years 69 (37–93) 66 (25–83) 68 (25–93)
Median time since diagnosis (range), months 32.2 (10.2–285.2) 24.4 (7.6–184.2) 30.6 (7.6–285.2)
Germline BRCA1/2 mutation, N (%)a
BRCA1 11 (6.4) 3 (6.1) 14 (6.4)
BRCA2 7 (4.1) 5 (10.2) 12 (5.5)
Histology, N (%)
High-grade serous 160 (93.6) 49 (100) 209 (95.0)
G3 Endometrioid 5 (2.9) 0 5 (2.3)
Carcinosarcoma 1 (0.6) 0 1 (0.4)
Missing 5 (2.9) 0 5 (2.3)
Number of prior treatment regimens
Median number of regimens (range) 1 (1–5) 2 (1–12) 1 (1–12)
1, N (%) 120 (70.2) 17 (34.7) 137 (62.3)
2, N (%) 39 (22.8) 23 (46.9) 62 (28.2)
3, N (%) 6 (3.5) 1 (2.0) 7 (3.2)
4, N (%) 1 (0.6) 2 (4.1) 3 (1.4)
44, N (%) 3 (1.7) 6 (12.3) 9 (4.0)
Data missing 2 (1.2) 0 2 (0.9)
aMutation status as recorded at time of study entry.
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the platinum-resistant patients and 34.9 months for platinum-
sensitive patients (Glasgow and Edinburgh patients, n¼ 68;
Supplementary Material 5).
Biopsies. Eighteen of the 220 (8.2%) consented patients did not
complete study-entry biopsy, most commonly because disease was
found to be unsuitable for biopsy during the procedure. Therefore,
202 patients completed study-entry biopsy procedure, including
118 image-guided biopsies, yielding a total of 216 relapse tumour
samples. Eleven patients also underwent a second biopsy procedure
(seven image-guided) upon subsequent progression, including one
patient whose study entry biopsy had been unsuccessful. Thus, a
total of 227 tumour samples were collected. Reflecting the pattern
of spread of HGSC, these samples were obtained from multiple
different anatomical locations (Table 2). The commonest sites were
lymph node (64 samples), peritoneum (53 samples), omentum (26
samples) and liver (17 samples). Out of the 125 image-guided
biopsy procedures (118 at study entry, 7 at second biopsy), needle
size information was available for 120: 17/120 (14.2%) used 14 G
needles, 49 (40.8%) 16 G and 54 (45.0%) 18 G.
Study-related AEs were recorded for image-guided biopsy
procedures (A full listing is given in Supplementary Material 6).
Twenty-two AEs of any grade were reported (20 baseline biopsy, 2
second biopsy) in 18/125 (14.4%) procedures (Table 3). Pain was
the commonest AE (16/22, 72.7%; 13 grade 1, 3 grade 2). The
frequency of AEs was not significantly higher for 14G (five events
in 17 biopsies) or 16G (6/49) needles compared to 18G (11/54;
P¼ 0.228). Pre-specified significant complications were reported in
3/125 (2.4%) biopsies; two for grade 2 pain and one for combined
grade 2 pain and grade 2 haemorrhage (liver haematoma). The
grade 2 haemorrhage was managed conservatively and did not
require transfusion or any active intervention. There was only one
other grade 2 AE, of vaginal discharge in one patient, which was
also managed conservatively. CUSUM control boundaries were not
crossed and all complications resolved without long-term sequelae.
Quality of biopsies. We analysed samples from the first 157
patients, of whom 15 did not successfully complete study-entry
biopsy. The remaining 142 patients yielded 184 samples
(Figure 1B). At pathology review, 21/184 (11.4%) samples from
14 patients were found to contain no or few tumour cells, leaving
163 tumour samples (88 from image-guided biopsies, 75 from
surgical). Following dissection (41 macrodissection, 122 micro-
dissection), median tumour cellularity was 65% (IQR 45%–75%).
The median DNA yield was 2.87 mg (IQR 0.78–8.19). Five samples
(3.1%) yielded o200 ng DNA, the minimum pre-specified for
genomic analyses, although 2 of these 5 were still sufficient for
tagged amplicon sequencing. For image-guided biopsies
(Figure 2A), median DNA yield was 1.96 mg (IQR 0.62–3.39),
whilst surgical sample median was significantly higher (4.64 mg
(IQR 1.96–10.14); Poo0.001). In image-guided biopsies
(Figure 2B), median yield was significantly higher for 14 G/16 G
needles (2.86 mg [IQR 0.85–5.54]) than for 18 G (0.89 mg (IQR
0.47–2.92), P¼ 0.011).
By anatomical location in image-guided biopsies specifically
(Figure 2C), the highest median DNA yields were obtained from
gynaecological organs (8.82 mg (IQR 3.16–13.36 mg)), peritoneum
(2.86 mg (IQR 0.62–4.56)) and lymph nodes (2.32 mg (IQR 0.63–
3.18)), although these differences did not reach statistical
significance. There was a significant correlation (Spearman
r¼ 0.304, Poo0.001) between tumour cellularity and overall
DNA yield (Figure 2D)
Using tagged amplicon next-generation sequencing (median read
depth 1086 ), TP53 mutations were identified in 94.4% (118/125)
patients (Figure 3A) with mean mutant allele frequency (MAF) 0.55.
These included 71 (60.2%) nonsynonymous (missense), 41 (34.7%)
loss of function mutations (nonsense, splicing and frameshift)
and 6 (5.1%) inframe indels. Mutations in KRAS, PIK3CA
and PTEN were identified in 4.8% (6/125), 2.4% (3/125) and 1.6%
(2/125) patients respectively. No mutations were detected in EGFR or
BRAF. Overall, we found a strong correlation between cellularity and
TP53 MAF (Figure 3B, Spearman r¼ 0.314, Poo0.001) and a
weaker, but still significant, correlation between DNA yield and
TP53 MAF (r¼ 0.220, P¼ 0.0034).
DISCUSSION
In this study, we demonstrate that obtaining tumour biopsies in
women with relapsed ovarian cancer is feasible and safe, and can
be co-ordinated across multiple academic centres. Moreover, we
demonstrate that patients with recurrent ovarian cancer are willing
to undergo a research biopsy for purely altruistic purposes;
treatment following the biopsy was at the local investigator’s
discretion and there was no investigational agent on offer.
In order to recruit 220 patients, we had to screen 519—the
commonest reason for non-participation was disease thought not
to be amenable to image-guided biopsy on review of imaging.
Thus, our image-guided biopsies were obtained from women with
relatively bulky disease. However, median OS (13.4 months and
34.9 months, respectively, for platinum-resistant and platinum-
sensitive patients) was comparable to that in the control arms
of recent large randomised studies (Aghajanian et al, 2012;
Pujade-Lauraine et al, 2014), and tagged amplicon sequencing
demonstrated near-universal TP53 mutation and low-frequency
mutations in KRAS, PIK3CA and PTEN, in keeping with previous
data in HGSC (Ahmed et al, 2010; TCGA, 2011; Ko¨bel et al, 2016).
Thus, we believe that our patients are similar to other trial
Table 2. Biopsy locations by sample
Anatomical location N¼ %
Lymph nodea 64 28.2
Peritoneum 53 23.3
Omentum 26 11.5
Liver 17 7.5
Gynaecological organb 14 6.2
Soft tissue (subcutaneous, chest or abdominal wall) 14 6.2
Bowel, serosa or mesentery 12 5.3
Diaphragm 4 1.8
Peri-splenic 4 1.8
Otherc 19 8.4
Total 227 100.0
aPelvic (14), para-aortic/retroperitoneal (13), other (37).
bVaginal vault (8), uterus, ovary/fallopian tube (6).
cBladder wall (3), brain (2), iliac fossa (2), pelvic/pelvic sidewall (2), breast (1), paracolic gutter
(1), para-sternal (1), perinephric (1), pleural (1), retro-caecal (1), small bowel (1), trachea (1),
lung (1), obturator fossa (1).
Table 3. Adverse events in 125 image-guided biopsy
procedures
Event typea Grade 1 Grade 2
Pain 13 3
Haemorrhage 3 1
Vaginal discharge 0 1
Otherb 1 0
aOne biopsy could have 41 adverse events. These events were reported from 19 biopsy
procedures in 18 patients.
bHaematoma.
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populations in relapsed ovarian cancer. Seven patients were found
to have TP53 wild-type tumours, three of which harboured KRAS
mutations. Two of these cases were diagnosed before the binary
grading of serous carcinomas was introduced and had been
originally classified as ‘grade 2 serous’ tumours. In other cases, the
reporting pathologists stated that grading was difficult or that there
were areas of borderline change. Thus, it is likely that these cases
represent low-grade serous carcinomas that were misclassified at
the time of original diagnosis.
Adverse events were generally rare, with grade 1 pain as the
commonest event following image-guided biopsy, recorded in 13
cases. There were only three expedited AEs, a figure comparable to
results reported from large single centre series (El-Osta et al, 2011;
Gomez-Roca et al, 2012), and one other grade 2 AE (vaginal
discharge), in one patient. However, it is clearly important
that patients are properly consented before research biopsy
procedures, and these data provide robust safety information to
inform the consent process in patients with relapsed ovarian cancer
in future.
We fixed samples in a methanol-based fixative that we have
previously shown to be superior to buffered formalin for genomic
studies (Piskorz et al, 2016). In addition, methanol fixation allows
samples to be transported and stored at ambient temperature and
analysed by IHC, both distinct advantages over snap-frozen
samples for a multi-centre study. We highlight that, although
11.4% (21/184) samples contained o20% tumour cells, only
three of the remaining 164 samples yielded no usable DNA. Thus,
overall 87% of the biopsies were fit-for-purpose. These figures are
comparable to the ARIEL2 study, which investigated genomic LOH
as a potential predictive biomarker of response to the PARP
inhibitor rucaparib (Swisher et al, 2017). In ARIEL2, 136/152
(89.5%) relapse biopsies yielded sufficient DNA for LOH analyses.
Three of the samples in our study with o200 ng yields utilised an
18 G needle—our results show that 14 G/16 G needles generate
higher DNA yields but do not cause more frequent AEs. We thus
recommend the use of larger gauge needles for biopsies where
genomic analyses are planned.
In terms of anatomical biopsy location, experience from the
MOSCATO-01 study indicated that bone biopsies were associated
with the lowest rates of tumour cellularity (Tacher et al, 2016). In
our series, there were no bone biopsies, given the pattern of
dissemination of HGSC. The commonest site of biopsy was lymph
node—the choice of biopsy site was at the discretion of the
radiologist undertaking the procedure for image-guided biopsies.
Thus, these were the most accessible sites in the participating
patients rather than the only sites of relapse. We found that
biopsies from gynaecological organs yielded the highest quantities
of DNA in image-guided procedures, although the differences
between biopsy sites were not significant. We found strong
correlation between tumour cellularity and TP53 mutant allele
fraction, as well as correlation between DNA yield and cellularity.
The correlation between total DNA yield and mutant allele fraction
was still significant, although more weakly than the other two
analyses. This suggests that, although DNA yield is important,
dissection of samples to ensure high tumour cellularity is critical
when processing biopsies for genomic studies.
The scientific purpose of the BriTROC programme will be to
investigate changes in cancer biology as tumours recur and develop
chemotherapy resistance. Intra-tumoural spatial heterogeneity
is a potential concern when examining single core biopsies in
patients with multi-site relapse, and the recent International
Cancer Genome Consortium analysis identified multiple separate
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reversion events in post-mortem analysis of a germline BRCA2
mutation carrier with HGSC (Patch et al, 2015). We have allowed
patients undergoing secondary debulking surgery to enter
BriTROC-1, and five of these patients have donated multiple
samples.
In early phase trials, there is evidence that patients are broadly
willing to undergo translational biopsies (Seah et al, 2013),
although rates of take-up are highest for mandatory biopsies (El-
Osta et al, 2011). Scheduling research biopsies in busy interven-
tional radiology departments can be challenging—we demonstrate
here that it is logistically possibly to do so, and centres received a
standard per-biopsy fee of d800 (approximately US$1000, h950) to
cover the cost of the scan (CT or ultrasound), the radiologist’s
time, the biopsy needle and fixative. There is variation in the
reporting of research biopsies (Freeman et al, 2013), and we believe
that it is essential that biomarker biopsy studies are reported
consistently to improve future trials. Such reports should include
complete details for biopsy sites, the number of biopsies, the
protocol for tissue analysis and overall outcome. BriTROC-1 shows
that research biopsies that are fit-for-purpose for genomic analyses
can be readily and safely obtained from women with recurrent
HGSC across multiple centres. Although the yields from surgical
biopsies were higher, image-guided biopsies are satisfactory, less
invasive and obviate the need for a general anaesthetic in patients
not scheduled for secondary debulking surgery. From these results,
we recommend the use of methanol fixation and of 14 G or 16 G
needles for biopsies as they are associated with optimum DNA
yield but no increase in AEs.
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